A multicentre prospective, observational, longitudinal cohort study in adult patients with suspected upper or lower respiratory infection (URTI/LRTI) to identify a spectrum of biomarkers in exhaled breath to discriminate participants with bacterial RTI from participants without.
Identification of chemical biomarkers in exhaled breath that potentially discriminates participants with bacterial RTI from participants without.
Additional endpoints explored will be variations of the chemical spectrum from all participants using a portable GC-IMS device (Breathspec) stratified by confounding factors, such as (but not limited to) gender, age, antibiotic therapy and smoking status.
Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine
People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.
Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.
KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.
DASH is a randomised clinical trial investigating a treatment to reverse the effects of blood-thinning medications.